Stellar Populations of UV-Selected Active Galactic Nuclei Host Galaxies at z ~ 2 - 3

We use stellar population synthesis modeling to analyze the host galaxy properties of a sample of 33 UV-selected, narrow-lined active galactic nuclei (AGNs) at z ~ 2 - 3. In order to quantify the contribution of AGN emission to host galaxy broadband spectral energy distributions (SEDs), we use the subsample of 11 AGNs with photometric coverage spanning from rest-frame UV through near-IR wavelengths. Modeling the SEDs of these objects with a linear combination of stellar population and AGN templates, we infer the effect of the AGN on derived stellar population parameters. We also estimate the typical bias in derived stellar populations for AGNs lacking rest-frame near-IR wavelength coverage, and develop a method for inferring the true host galaxy properties. We compare AGN host galaxy properties to those of a sample of UV-selected, star-forming non-AGNs in the same redshift range, including a subsample carefully matched in stellar mass. Although the AGNs have higher masses and SFRs than the full non-active sample, their stellar population properties are consistent with those of the mass-selected sample, suggesting that the presence of an AGN is not connected with the cessation of star-formation activity in star-forming galaxies at z ~ 2 - 3. We suggest that a correlation between M_BH and galaxy stellar mass is already in place at this epoch. Assuming a roughly constant Eddington ratio for AGNs at all stellar masses, we are unable to detect the AGNs in low-mass galaxies because they are simply too faint.Comment: 30 pages, 16 figures, ApJ accepted. Replaced with accepted versio

cAMP-Signalling Regulates Gametocyte-Infected Erythrocyte Deformability Required for Malaria Parasite Transmission.

Blocking Plasmodium falciparum transmission to mosquitoes has been designated a strategic objective in the global agenda of malaria elimination. Transmission is ensured by gametocyte-infected erythrocytes (GIE) that sequester in the bone marrow and at maturation are released into peripheral blood from where they are taken up during a mosquito blood meal. Release into the blood circulation is accompanied by an increase in GIE deformability that allows them to pass through the spleen. Here, we used a microsphere matrix to mimic splenic filtration and investigated the role of cAMP-signalling in regulating GIE deformability. We demonstrated that mature GIE deformability is dependent on reduced cAMP-signalling and on increased phosphodiesterase expression in stage V gametocytes, and that parasite cAMP-dependent kinase activity contributes to the stiffness of immature gametocytes. Importantly, pharmacological agents that raise cAMP levels in transmissible stage V gametocytes render them less deformable and hence less likely to circulate through the spleen. Therefore, phosphodiesterase inhibitors that raise cAMP levels in P. falciparum infected erythrocytes, such as sildenafil, represent new candidate drugs to block transmission of malaria parasites

Is looped nasogastric tube feeding more effective than conventional nasogastric tube feeding for dysphagia in acute stroke?

Background: Dysphagia occurs in up to 50% of patients admitted to hospital with acute strokes with up to 27% remaining by seven days. Up to 8% continue to have swallowing problems six months after their stroke with 1.7% still requiring enteral feeding. Nasogastric tubes (NGT) are the most commonly used method for providing enteral nutrition in early stroke, however they are easily and frequently removed leading to inadequate nutrition, early PEG (Percutaneous Endoscopic Gastrostomy) insertion or abandoning of feeding attempts. Looped nasogastric tube feeding may improve the delivery of nutrition to such patients. Methods: Three centre, two arm randomised controlled trial, with 50 participants in each arm comparing loop (the intervention) versus conventional nasogastric tube feeding. The primary outcome measure is proportion of intended feed delivered in the first 2 weeks. The study is designed to show a mean increase of feed delivery of 16% in the intervention group as compared with the control group, with 90% power at a 5% significance level. Secondary outcomes are treatment failures, mean volume of feed received, adverse events, cost-effectiveness, number of chest x-rays, number of nasogastric tubes and tolerability

Soil corrosion monitoring near a pipeline under CP

Electrochemical noise (EN), linear polarization resistance (LPR), and harmonic distortion analysis (HDA) were used with three-electrode probes to monitor the corrosion occurring in soil in dry and wet conditions near a gas pipeline under cathodic protection. The test site was a cathodic protection (CP) test station where impressed current CP was applied to a 2 in. (5.1 cm) diameter FBE coated steel pipe using an 84 in. (0.2 m) TA-2 high-silicon cast iron anode. Electrochemical measurements were made at three locations, two inside the CP field and one outside the CP field. Electrochemical measurements were first made with the CP system off to establish the baseline corrosion and then with increasing levels of CP. The degree of protection was based on polarized potential and the adequacy of protection was determined by depolarization measurements. CP of an adjacent pipeline did not affect the measurement of either corrosion rate or pitting factor when using buried soil corrosion probes and the EN, LPR, and HDA techniques

Is council tax valuation band a predictor of mortality?

BACKGROUND: All current UK indices of socio-economic status have inherent problems, especially those used to govern resource allocation to the health sphere. The search for improved markers continues: this study proposes and tests the possibility that Council Tax Valuation Band (CTVB) might match requirements. PRESENTATION OF THE HYPOTHESIS: To determine if there is an association between CTVB of final residence and mortality risk using the death registers of a UK general practice. TESTING THE HYPOTHESIS: Standardised death rates and odds ratios (ORs) for groups defined by CTVB of dwelling (A – H) were calculated using one in four denominator samples from the practice lists. Analyses were repeated three times – between number of deaths and CTVB of residence of deceased 1992 – 1994 inclusive, 1995 – 1997 inc., 1998 – 2000 inc. In 856 deaths there were consistent and significant differences in death rates between CTVBs: above average for bands A and B residents; below average for other band residents. There were significantly higher ORs for A, B residents who were female and who died prematurely (before average group life expectancy). IMPLICATIONS OF THE HYPOTHESIS: CTVB of final residence appears to be a proxy marker of mortality risk and could be a valuable indicator of health needs resource at household level. It is worthy of further exploration

Ixazomib-lenalidomide-dexamethasone in routine clinical practice: Effectiveness in relapsed/refractory multiple myeloma

[Aim]: To evaluate the effectiveness and safety of ixazomib-lenalidomide-dexamethasone (IRd) in relapsed/refractory multiple myeloma in routine clinical practice. Patients & methods: Patient-level data from the global, observational INSIGHT MM and the Czech Registry of Monoclonal Gammopathies were integrated and analyzed.[Results]: At data cut-off, 263 patients from 13 countries were included. Median time from diagnosis to start of IRd was 35.8 months; median duration of follow-up was 14.8 months. Overall response rate was 73%, median progression-free survival, 21.2 months and time-to-next therapy, 33.0 months. Ixazomib/lenalidomide dose reductions were required in 17%/36% of patients; 32%/30% of patients discontinued ixazomib/lenalidomide due to adverse events.[Conclusion]: The effectiveness and safety of IRd in routine clinical practice are comparable to those reported in TOURMALINE-MM1.This work was supported by Millennium Pharmaceuticals, Inc., Cambridge, MA, USA, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited

Cohort profile for the STratifying Resilience and Depression Longitudinally (STRADL) study:A depression-focused investigation of Generation Scotland, using detailed clinical, cognitive, and neuroimaging assessments

Grant information: STRADL is supported by the Wellcome Trust through a Strategic Award (104036/Z/14/Z). GS:SFHS received core support from the CSO of the Scottish Government Health Directorates (CZD/16/6) and the Scottish Funding Council (HR03006). ADM is supported by Innovate UK, the European Commission, the Scottish Funding Council via the Scottish Imaging Network SINAPSE, and the CSO. HCW is supported by a JMAS SIM Fellowship from the Royal College of Physicians of Edinburgh, by an ESAT College Fellowship from the University of Edinburgh, and has received previous funding from the Sackler Trust. LR has previously received financial support from Pfizer (formerly Wyeth) in relation to imaging studies of people with schizophrenia and bipolar disorder. JDH is supported by the MRC. DJM is an NRS Clinician, funded by the CSO. RMR is supported by the British Heart Foundation. ISP-V and MRM are supported by the NIHR Biomedical Research Centre at the University Hospitals Bristol NHS Foundation Trust and the University of Bristol. The views expressed in this publication are those of the author(s) and not necessarily those of the NHS, the National Institute for Health Research or the Department of Health; and MRM is also supported by the MRC MC_UU_12013/6). JMW is supported by MRC UK Dementia Research Institute and MRC Centre and project grants, EPSRC, Fondation Leducq, Stroke Association, British Heart Foundation, Alzheimer Society, and the European Union H2020 PHC-03-15 SVDs@Target grant agreement (666881). DJP is supported by Wellcome Trust Longitudinal Population Study funding (216767/Z/19/Z) the Eva Lester bequest to the University of Edinburgh. AMM is additionally supported by the MRC (MC_PC_17209, MC_PC_MR/R01910X/1, MR/S035818/1), The Wellcome Trust (216767/Z/19/Z ), The Sackler Trust, and has previously received research funding from Pfizer, Eli Lilly, and Janssen. Both AMM and IJD are members of The University of Edinburgh Centre for Cognitive Ageing and Cognitive Epidemiology, part of the cross council Lifelong Health and Wellbeing Initiative (MR/K026992/1); funding from the BBSRC and MRC is gratefully acknowledged. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscriptPeer reviewedPublisher PD

Study Protocol, Sample Characteristics, and Loss to Follow-Up: The OPPERA Prospective Cohort Study

When studying incidence of pain conditions such as temporomandibular disorders (TMDs), repeated monitoring is needed in prospective cohort studies. However, monitoring methods usually have limitations and, over a period of years, some loss to follow-up is inevitable. The OPPERA prospective cohort study of first-onset TMD screened for symptoms using quarterly questionnaires and examined symptomatic participants to definitively ascertain TMD incidence. During the median 2.8-year observation period, 16% of the 3,263 enrollees completed no follow-up questionnaires, others provided incomplete follow-up, and examinations were not conducted for one third of symptomatic episodes. Although screening methods and examinations were found to have excellent reliability and validity, they were not perfect. Loss to follow-up varied according to some putative TMD risk factors, although multiple imputation to correct the problem suggested that bias was minimal. A second method of multiple imputation that evaluated bias associated with omitted and dubious examinations revealed a slight underestimate of incidence and some small biases in hazard ratios used to quantify effects of risk factors. Although “bottom line” statistical conclusions were not affected, multiply-imputed estimates should be considered when evaluating the large number of risk factors under investigation in the OPPERA study

The Characteristic Star Formation Histories of Galaxies at Redshifts z~2-7

A large sample of spectroscopically confirmed galaxies at 1.4<z<3.7, with complementary imaging in the near- and mid-IR from the ground and from Hubble and Spitzer, is used to infer the average star formation histories (SFHs) of typical galaxies from z~7 to 2. For a subset of 302 galaxies at 1.5<z<2.6, we perform a comparison of star formation rates (SFRs) determined from SED modeling (SFRs[SED]) and those calculated from deep Keck UV and Spitzer/MIPS 24 micron imaging (SFRs[IR+UV]). Exponentially declining SFHs yield SFRs[SED] that are 5-10x lower on average than SFRs[IR+UV], indicating that declining SFHs may not be accurate for typical galaxies at z>2. The SFRs of z~2-3 galaxies are directly proportional to their stellar masses M*, with unity slope---a result that is confirmed with Spitzer/IRAC stacks of 1179 UV-faint (R>25.5) galaxies---for M*>5e8 Msun and SFRs >2 Msun/yr. We interpret this result in the context of several systematic biases that can affect determinations of the SFR-M* relation. The average specific SFRs at z~2-3 are similar within a factor of two to those measured at z>4, implying an average SFH where SFRs increase with time. A consequence of these rising SFHs is that (a) a substantial fraction of UV-bright z~2-3 galaxies had faint sub-L* progenitors at z>4; and (b) gas masses must increase with time from z=7 to 2, over which time the net cold gas accretion rate---as inferred from the specific SFR and the Kennicutt-Schmidt relation---is ~2-3x larger than the SFR . However, if we evolve to higher redshift the SFHs and masses of the halos that are expected to host L* galaxies at z~2, we find that <10% of the baryons accreted onto typical halos at z>4 actually contribute to star formation at those epochs. These results highlight the relative inefficiency of star formation even at early cosmic times when galaxies were first assembling. [Abridged]Comment: 34 pages, 29 figures, 8 tables, accepted for publication in Ap

Effects of antiplatelet therapy on stroke risk by brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases: subgroup analyses of the RESTART randomised, open-label trial

Background Findings from the RESTART trial suggest that starting antiplatelet therapy might reduce the risk of recurrent symptomatic intracerebral haemorrhage compared with avoiding antiplatelet therapy. Brain imaging features of intracerebral haemorrhage and cerebral small vessel diseases (such as cerebral microbleeds) are associated with greater risks of recurrent intracerebral haemorrhage. We did subgroup analyses of the RESTART trial to explore whether these brain imaging features modify the effects of antiplatelet therapy